Chemokine System Changes Drive Age-Related Macular Degeneration and Influence Treatment Outcomes
Investigative Ophthalmology & Visual Science · 2025-05-06 · 66 (5) · 14
DOI: 10.1167/iovs.66.5.14 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2025-05-06. Written by Alexander Kai Thomsen and 6 co-authors. Institution: Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark. Major MEDLINE topics: Chemokines, Receptors, Chemokine, Wet Macular Degeneration. Cited 7 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
The chemokine system is associated with age-related macular degeneration (AMD), shown in previous studies. In this study, we investigate these chemokines and chemokine receptors and their association with treatment response in neovascular AMD (nAMD), and association to intermediate AMD (iAMD).
Methods
In this prospective cohort study, patients with nAMD, iAMD, and healthy controls were included. The initial and 1-year treatment response was evaluated in patients with nAMD. Plasma chemokine concentrations of CCL2, CCL3, CCL4, CCL20, CXCL8, and CXCL10 were measured with immunoassays. Chemokine receptor expression levels of CCR1, CCR2, CCR5, CCR6, CXCR2, CXCR3, and CX3CR1 on circulating T cells and monocytes were measured with flow cytometry. Correlation network analyses were performed of the chemokine system. Genotyping for CFH and ARMS2 risk polymorphisms was performed in patients with nAMD.
Results
Patients with nAMD with poor initial treatment response had significantly lower proportions of CD4+CXCR3+, CCR5+ classical monocytes, and CCR2+ non-classical monocytes compared with good initial responders (all P < 0.05). Patients with nAMD with poor 1-year treatment response had significantly lower CD4+CXCR3+ and CCR2+ non-classical monocytes compared to good 1-year responders (both P < 0.05). Correlation networks revealed a more complex regulation in partial and poor initial treatment responders. Multiple chemokines and chemokine receptors significantly correlated with the risk genotypes of CFH and ARMS2.
Conclusions
Patients with nAMD with poor treatment response had dysregulation of the chemokine system. The chemokine system might be a potential target of novel treatment in nAMD. Further studies are needed to clarify the chemokine system's role in nAMD treatment response.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Cite
APA
Thomsen, A. K., Steffensen, M. A., Nielsen, A. T., Vorum, H., Honoré, B., Nissen, M. H., & Sørensen, T. L. (2025). Chemokine System Changes Drive Age-Related Macular Degeneration and Influence Treatment Outcomes. Investigative Ophthalmology & Visual Science, 66(5), 14. https://doi.org/10.1167/iovs.66.5.14
Vancouver
Thomsen AK, Steffensen MA, Nielsen AT, Vorum H, Honoré B, Nissen MH, et al. Chemokine System Changes Drive Age-Related Macular Degeneration and Influence Treatment Outcomes. Investigative Ophthalmology & Visual Science. 2025;66(5):14. doi:10.1167/iovs.66.5.14
BibTeX
@article{Thomsen2025,
author = {Thomsen, Alexander Kai and Steffensen, Maria Abildgaard and Nielsen, Amalie Thomsen and Vorum, Henrik and Honoré, Bent and Nissen, Mogens Holst and Sørensen, Torben Lykke},
title = {Chemokine System Changes Drive Age-Related Macular Degeneration and Influence Treatment Outcomes},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
volume = {66},
number = {5},
pages = {14},
doi = {10.1167/iovs.66.5.14}
}
EUVIMED